Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ Plans To Triple Spending On Russia Drugs Over Next Five Years

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca said it plans to at least triple its current investment in Russia, to as much as $1.2 billion by 2017 to develop new products in targeted drugs, biomarkers, predictive medicine and design of clinical studies.

You may also be interested in...



Caplin Partners With Xellia For Five Injectables

With a pipeline of over 35 ANDAs, India's Caplin Steriles plans to launch five generic injectables through a strategic partnership with Xellia Pharma in the US market. Out of the five ANDAs, one has been approved and is ready for launch.

Sanofi Has EU Insulin Aspart Biosimilar Approval

Sanofi has received formal approval from the European Commission for its insulin aspart biosimilar.

Rx-To-OTC Switch And RWE Key To Creating ‘Crisis Proof’ European Medicines System

Europe's self-care industry urges the European Commission to use Rx-to-OTC switch and real world evidence to widen access to OTC medicines in the region as part of its new pharmaceutical strategy. 

Topics

UsernamePublicRestriction

Register

LL025498

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel